News | April 11, 2026
Zydus improves ESG rating to 68, up from 66 last year
The improved score reflects a stronger ESG profile for the Ahmedabad-based drugmaker
The improved score reflects a stronger ESG profile for the Ahmedabad-based drugmaker
The new single-pill therapy combines cilnidipine, telmisartan and metoprolol, bringing together three established antihypertensive agents with complementary mechanisms
A major highlight of the event was the launch of several publications and digital initiatives, including a certification course on the Ayush Grid portal
Board approves allotment of shares to promoter Shankar Varadharajan following warrant conversion under SEBI Regulation 30 disclosure
Final approval for diabetes and heart-failure drug opens access to a $10.5 billion US market opportunity, with shared exclusivity benefits.
Collaboration to study integration of AI-enabled VR solutions into medical and nursing curricula
Board approves five-year appointment, subject to shareholder nod through postal ballot
Paid-up equity capital rises to Rs 973.19 crore following allotment to eligible employees
Rs 66 lakh acquisition will support DNA engineering and novel cell-gene therapy alternatives to conventional chemotherapy
Parliament clears reform bill replacing jail terms for procedural lapses with graded monetary penalties across key health laws
Subscribe To Our Newsletter & Stay Updated
